On June 7, advocacy groups, Alzheimer’s patients, and their families celebrated as the US Food and Drug Administration (FDA) authorized the drug Aducanumab to treat Alzheimer’s. On the surface, this novel therapy—the first approved in 2003—seems massively encouraging for both the patients afflicted with Alzheimer’s and society as a whole. Unfortunately, in authorizing Aducanumab, the […]